Tyson Kim
Chief Executive Officer chez SYNTEKABIO, INC.
Profil
Tyson Kim currently works at Syntekabio, Inc, as Chief Executive Officer from 2015 and Radexel Co. Ltd., as Chief Executive Officer.
Postes actifs de Tyson Kim
| Sociétés | Poste | Début |
|---|---|---|
| SYNTEKABIO, INC. | Chief Executive Officer | 01/01/2015 |
Radexel Co. Ltd.
 Radexel Co. Ltd. Medical SpecialtiesHealth Technology Radexel Co. Ltd. is a medical technology company based in Seoul, KR. The company was founded in 2018 by CEO Tyson Kim on the basis of Seoul Asan Medical Center development technology. Radexel is developing a radiation therapy device that treats cancer precisely with the world's first developed magnetic-radiation fusion technology and AI treatment plan. The device reduces side effects of normal tissue adjacent to cancer and improves treatment effect. It is also low-cost and compact, and can be installed in the same space as the existing radiation therapy device. | Chief Executive Officer | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SYNTEKABIO, INC. | Technology Services |
| Entreprise privées | 1 |
|---|---|
Radexel Co. Ltd.
Radexel Co. Ltd. Medical SpecialtiesHealth Technology Radexel Co. Ltd. is a medical technology company based in Seoul, KR. The company was founded in 2018 by CEO Tyson Kim on the basis of Seoul Asan Medical Center development technology. Radexel is developing a radiation therapy device that treats cancer precisely with the world's first developed magnetic-radiation fusion technology and AI treatment plan. The device reduces side effects of normal tissue adjacent to cancer and improves treatment effect. It is also low-cost and compact, and can be installed in the same space as the existing radiation therapy device. | Health Technology |
